

PLEASE STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

In Re Application of: KALLED et al.

Application No.: 10/505,376

Group Art Unit: Not Yet Assigned

Filed: August 20, 2004

Examiner: Not Yet Assigned


For: USE OF BCMA AS AN IMMUNOREGULATORY AGENT

1. Information Disclosure Statement (2 pages);
2. PTO/SB/08 form (9 pages); and
3. References cited in IDS (4 boxes- Shipped By Express Mail EV 618318762 US, EV 618318759 US, EV 618318745 US, EV 618318731 US.).

Dated: April 5, 2005

Docket No.: 08201.0028-00000

LAM/KXL/kmb - Mail Drop CAMB



J007 Rec'd PCT/PTO n 5 APR 2005



04-06-05 JG07 Rec'd PCT/PTO n 5 APR 2005 PCT

PATENT
Customer No. 22,852
Attorney Docket No. 08201.0028-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
Susan L. Kalled and Hugh Reid)	Group Art Unit: Not Yet Assigned
Application No.: 10/505,376)	Examiner: Not Yet Assigned
Filed: August 20, 2004)	
For: USE OF BCMA AS AN IMMUNOREGULATORY AGENT)	Confirmation No.: Not Yet Assigned

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached PTO/SB/08 form. This Information Disclosure Statement is being filed before issuance of a first Office Action for the above-referenced application.

Based on reasonable inquiry, no document listed in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and no document listed in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement. Copies of the listed foreign and non-patent literature documents are attached. Copies of the U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form. PCT Publication Nos. WO 03/055979 and WO 02/02641 contain voluminous sequence listings which

have been omitted in this submission. If the Examiner requires complete copies of these documents, please contact the undersigned attorney.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: 4.4.05

By: 
Konstantin M. Linnik
Reg. No. 56,309

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

9

Application Number

10/505,376

Filing Date

August 20, 2004

First Named Inventor

KALLED

Art Unit

Not Yet Assigned

Examiner Name

Not Yet Assigned

Attorney Docket Number

08201.0028-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initial*	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		5,595,721	01/21/1997	Kaminski et al.	
		5,969,102	10/19/1999	Bram et al.	
		6,297,367	10/02/2001	Tribouley	
		6,316,222	11/13/2001	Bram et al.	
		6,403,770	06/11/2002	Yu et al.	
		6,475,986	11/05/2002	Aggarwal	
		6,541,224	04/01/2003	Yu et al.	
		6,475,987	11/05/2002	Shu	
		6,623,941	09/23/2003	Ruben et al.	
		6,689,579	02/10/2004	Yu et al.	
		6,869,605	03/22/2005	Browning et al.	
		US-2001-0010925	08/02/2001	Wiley	
		US-2002-0037852	03/28/2002	Browning et al.	
		US-2002-0004587	01/10/2002	Miller et al.	
		US-2002-0055624	05/09/2002	Wiley	
		US-2002-0064829	05/30/2002	Yu et al.	
		US-2002-0115112	08/22/2002	Yu et al.	
		US-2002-0165156A1	11/07/2002	Browning et al.	
		US-2002-0172674A1	11/21/2002	Jeffrey et al.	
		US-2003-0022239	01/30/2003	Baker et al.	
		US-2003-0023038	01/30/2003	Rennert	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	9	Attorney Docket Number	08201.0028-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initial*	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-2003-0053984	03/20/2003	Tschopp et al.	
		US-2003-0082175	05/01/2003	Schneider et al.	
		US-2003-0095967	05/23/2003	MacKay et al.	
		US-2003-0119149	06/26/2003	Reddy	
		US-2003-0148445	08/07/2003	Shu	
		US-2003-0166546	09/24/2003	Aggarwal	
		US-2003-0175208	09/18/2003	Yu et al.	
		US-2003-0194743	10/16/2003	Beltzer et al.	
		US-2003-0211509	11/13/2003	Wiley	
		US-2003-0100068	05/29/2003	Lam et al.	
		US-2003-0100074	05/29/2003	Yu et al.	
		US-2003-0108992	06/12/2003	Lenardo et al.	
		US-2003-0148454	08/07/2003	Marshak-Rothstein et al.	
		US-2003-0166864	09/04/2003	Yu et al.	
		US-2003-0194745	10/16/2003	McDowell et al.	
		US-2003-0198640	10/23/2003	Yu et al.	
		US-2004-0013674	01/22/2004	Ambrose et al.	
		US-2004-0072188	04/15/2004	Ambrose et al.	
		US-2004-0028658	02/12/2004	Faustman	
		US-2004-0033511	02/19/2004	Pfizenmaier et al.	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	10/505,376
				<i>Filing Date</i>	August 20, 2004
				<i>First Named Inventor</i>	KALLED
				<i>Art Unit</i>	Not Yet Assigned
				<i>Examiner Name</i>	Not Yet Assigned
Sheet	3	of	9	<i>Attorney Docket Number</i>	08201.0028-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initial*	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-2004-0038349	02/26/2004	Hilbert et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initial*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation Yes or No
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		EP 0 869 180	06/09/1999	SmithKline Beecham Corp.		
		EP 0 921 194	06/09/1999	Eli Lilly & Co.		
		EP 1 146 892	08/20/2003	Biogen Inc. et al.		
		WO 97/33902	09/18/1997	Human Genome Sciences		
		WO 98/18921	05/07/1998	Human Genome Sciences		
		WO 98/27114	06/25/1998	Schering Corp.		
		WO 98/39361	09/11/1998	The Children's Hospital		
		WO 98/55620	12/10/1998	Regeneron Pharmaceuticals, Inc.		
		WO 98/55621	12/10/1998	Regeneron Pharmaceuticals, Inc.		
		WO 99/04001	01/28/1999	Zymogenetics, Inc.		
		WO 99/11791	03/11/1999	University of Washington		
		WO 99/12964	03/18/1999	Biogen Inc.		
		WO 99/12965	03/18/1999	Biogen Inc.		
		WO 99/26463	06/03/1999	Eli Lilly & Co.		
		WO 99/33980	07/08/1999	Chiron Corp.		
		WO 00/26244	05/11/2000	Government of U.S.A. et al.		

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	4	of	9	Attorney Docket Number	08201.0028-00000

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation Yes or No
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 00/39295	07/06/2000	Glaxo Group Limited		
		WO 00/40716	07/13/2000	Zymogenetics, Inc.		
		WO 00/43032	07/27/2000	Biogen Inc.		
		WO 00/45836	08/10/2000	Research Development Foundation		
		WO 00/47740	08/17/2000	Amgen Inc.		
		WO 00/50597	08/31/2000	Human Genome Sciences		
		WO 00/50633	08/31/2000	The General Hospital Corp.		
		WO 00/60079	10/12/2000	Chiron Corp.		
		WO 00/68378	11/16/2000	National Jewish Medical and Research Center		
		WO 00/77256	12/21/2000	Human Genome Sciences		
		WO 01/40466	06/07/2001	Genetech, Inc.		
		WO 01/42298	06/14/2001	Kornbluth		
		WO 01/49318	07/12/2001	TR Associates L.L.C.		
		WO 01/58949	08/16/2001	Biogen, Inc.		
		WO 01/90304	11/29/2001	Human Genome Sciences		
		WO 01/96528	12/20/2001	Human Genome Sciences		
		WO 02/02641	01/10/2002	Human Genome Sciences et al.		
		WO 02/092620	11/21/2002	Amgen, Inc.		
		WO 02/15930	02/28/2002	Duke University		

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	5	of	9	Attorney Docket Number	08201.0028-00000

FOREIGN PATENT DOCUMENTS						
Examiner Initial*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation Yes or No
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 02/18620	03/07/2002	Human Genome Sciences		
		WO 02/08284	01/31/2002	Genentech, Inc.		
		WO 02/38766	05/16/2002	Zymogenetics		
		WO 03/001877	01/09/2003	Gene Logic, Inc.		
		WO 03/014294	02/20/2003	Genentech, Inc.		
		WO 03/022877	03/20/2003	Biogen Inc.		
		WO 03/024991	03/27/2003	Amgen Inc.		
		WO 03/033658	04/24/2003	Human Genome Sciences		
		WO 03/035846	05/01/2003	National Jewish Medical and Research Center		
		WO 03/040307	05/15/2003	Human Genome Sciences		
		WO 03/050134	06/19/2003	Human Genome Sciences		
		WO 03/055979	07/10/2003	Human Genome Sciences		
		WO 03/060071	07/24/2003	Human Genome Sciences et al.		
		WO 03/060072	07/24/2003	Immunex Corp.		
		WO 04/016737	02/26/2004	Eli Lilly and Company		
		WO 04/035735	04/29/2004	Genentech, Inc.		
		WO 05/005462	01/20/2005	Genentech, Inc.		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	6	of	9	Attorney Docket Number	08201.0028-00000

NON PATENT LITERATURE DOCUMENTS

		International Search Report, International Application No. PCT/US00/01788.
		Colman P.M., "Effects of amino acid sequence changes on antibody-antigen interaction," 55 th Forum in Immunol., pgs. 33-36 (1994)
		Dang et al, "SLE-Like Autoantibodies and Sjögren's Syndrome-Like Lymphoproliferation in TGF- β Knockout Mice," <i>J. Immunol.</i> , 155:3205-3212 (1995)
		Do et al., "Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response," <i>J. Exp. Med.</i> 192(7):953-964 (2000)
		EMBL Database entry, ID No. AA682496.
		EMBL Database entry, ID No. H58828.
		Furie et al, "Safety, Pharmacokinetic and Pharmacodynamic Results of a Phase 1 Single and Double Dose-Escalation Study of LymphoStat-B in SLE Patients," American College of Rheumatology (ACR), 67 th Annual Scientific meeting, <i>Abstract</i> . 922 (Oct. 23-28, 2003)
		Gallagher et al, "A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF- α antibody afelimomab in patients with sepsis syndrome," <i>Intensive Care Med.</i> , 27:1169-1178 (2001)
		GenBank Accession No. AK008142, Published February 16, 2001
		Gordon et al., "BAFF/Blys Receptor 3 Comprises a Minimal TNF Receptor-Like Module that Encodes a Highly Focused Ligand-Binding Site," <i>Biochemistry</i> 42:5977-5983 (2003)
		Gras et al, "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes," <i>Intl. Immunol.</i> , 7:1093-1106 (1995)
		Gross et al, "TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease," <i>Nature</i> , 404:995-999 (2000)
		Hahne et al, "APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth," <i>J. Exp. Med.</i> , 188:1185-1190 (1998)
		Harlow E. and Lane D., <i>Antibodies A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, pgs. 141-155 (1988)
		Kalled et al, "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders," <i>Expert. Opin. Ther. Targets</i> , 7(1):115-123 (2003)
		Kashii et al, "CONSTITUTIVE EXPRESSION AND ROLE OF THE TNF FAMILY LIGANDS IN APOPTOTIC KILLING OF TUMOR CELLS BY HUMAN NK CELLS," <i>J. Immunol.</i> , 163:5358-66 (2003)

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	7	of	9	Attorney Docket Number	08201.0028-00000

NON PATENT LITERATURE DOCUMENTS

		Kayagaki et al, "BAFF/BlyS Receptor 3 Binds the B Cell Survival Factor BAFF Ligand through a Discrete Surface Loop and Promotes Processing of NF- κ B2," <i>Immunity</i> , Vol. 10, 17(4):515-524 (2002)
		Khare et al, "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>PNAS USA</i> , 97:3370-3375 (2000)
		Khare et al., "The role of TALL-1 and APRIL in immune regulations," <i>Trends Immunol.</i> 22(2):61-63 (2001)
		Kogan et al, "A Single Amino Acid Residue Can Determine the Ligand Specificity of E-selectin," <i>J. Biol. Chem.</i> , 270(23):14047-55 (1995)
		Kwon et al, "Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes," <i>Curr. Opinion in Immunol.</i> , 340-345 (1999)
		Laabi et al, "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma," <i>EMBO J.</i> , 11:3897-3904 (1992)
		Laabi et al, "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed," <i>Nucleic Acids Res.</i> , 22:1147-1154 (1994)
		Mackay et al, "Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations," <i>J. Exp. Med.</i> , 190:1697-1710 (1999)
		Mackay, F. and Ambrose, C., "The TNF family members BAFF and APRIL: the growing complexity," <i>Cytokine & Growth Factor Reviews</i> , 14:311-324 (2003)
		Madry et al, "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily," <i>Intl. Immunol.</i> , 10:1693-1702 (1998)
		Marietta et al, "The level of BlyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome," <i>Ann Rheum Dis.</i> , 62:168-171 (2003)
		Moore et al, "BlyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator," <i>Science</i> , 285:260-263 (1999)
		Mukhopadhyay et al, "Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor- κ B, and c-Jun NH ₂ -Terminal Kinase," <i>J. Biol. Chem.</i> , 274:15978-15981 (1999)
		Ngo et al, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>Birkhauser</i> , ch. 14:491-494 (1994)

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	8	of	9	Attorney Docket Number	08201.0028-00000

NON PATENT LITERATURE DOCUMENTS

		Parry et al, "Pharmacokinetics and Immunological Effects of Exogenously Administered Recombinant Human B Lymphocyte Stimulator (BlyS) in Mice," <i>Journ. Pharm. Exp. Ther.</i> , 296(2):396-404 (2001)
		Pitti et al, "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer," <i>Nature</i> , 396:699-703 (1998)
		Schneider et al, "BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth," <i>J. Exp. Med.</i> , 189:1747-1756 (1999)
		Shu, H.B. and Johnson, H, "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1," <i>PNAS USA</i> , 97:9156-9161 (1999)
		Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," <i>J. Leukocyte Biol.</i> 65:680-683 (1999)
		Stump et al, "Human Genome Sciences Initiates Trial of a New Drug for Systemic Lupus Erythematosus and Other Autoimmune Diseases," <i>HGS Press Release</i> , pgs. 1-4 and <i>Human Genome Sciences Product Guides</i> , pgs. 1-9 and pgs. 1-13 (Nov. 2001)
		Thompson et al, "BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population," <i>J. Exp. Med.</i> , 192:129-135 (2000)
		Thompson et al, "BAFF interacts with the orphan receptor, BCMA," <i>Scandinavian J. of Immunol., Abstract</i> , 65 (2000)
		Thompson, J.S. et al. "BAFF-R, A Newly Identified TNF Receptor That Specifically Interacts with BAFF," <i>Science</i> 293:2108-211 (2001)
		Von Bülow et al, "Regulation of the T-Independent Humoral Response by TACI," <i>Immunity</i> , 14:573-582 (2001)
		Ward PA and Mulligan MS, "Blocking of adhesion molecules <i>in vivo</i> as anti-inflammatory therapy," <i>Ther Immunol</i> , 1:165-171 (1994)
		Ware CF, "APRIL and BAFF Connect Autoimmunity and Cancer," <i>J Exp Med.</i> , 192(11):F35-37 (2000)
		Wendy et al, "Effects of LymphoStat-B, a BlyS Antagonist, when Administered Intravenously to Cynomolgus Monkeys," American College of Rheumatology (ACR), 67 th Annual Scientific meeting, Abstract, 1537 (Oct. 23-28, 2003)
		Wu et al., "Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI is a High Affinity Receptor of TNF Family Members APRIL and BlyS," <i>J. Biol. Chem.</i> 275(45):35478-35485 (2000)

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	10/505,376
				<i>Filing Date</i>	August 20, 2004
				<i>First Named Inventor</i>	KALLED
				<i>Art Unit</i>	Not Yet Assigned
				<i>Examiner Name</i>	Not Yet Assigned
Sheet	9	of	9	<i>Attorney Docket Number</i>	08201.0028-00000

NON PATENT LITERATURE DOCUMENTS		
		Xia et al, "TACI is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation," <i>J. Exp. Med.</i> , 192:137-143 (2000)
		Yan, M. et. al, "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency," <i>Curr. Biol.</i> 11:1547-1552 (2001)
		Yu et al, "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," <i>Nat. Immun.</i> , 1:252-256 (2000)
Examiner		Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		